NASDAQ:CMND Clearmind Medicine (CMND) Stock Price, News & Analysis $1.05 -0.01 (-0.94%) Closing price 04:00 PM EasternExtended Trading$1.05 +0.00 (+0.10%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Clearmind Medicine Stock (NASDAQ:CMND) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Clearmind Medicine alerts:Sign Up Key Stats Today's Range$1.05▼$1.0950-Day Range$0.96▼$1.1952-Week Range$0.80▼$2.18Volume144,949 shsAverage Volume1.99 million shsMarket Capitalization$5.74 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Clearmind Medicine, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia. Clearmind’s pipeline includes multiple preclinical and early clinical candidates. Among these is an iboga alkaloid analog designed to treat neuropathic pain and opioid use disorder, as well as a series of next-generation psychoplastogens for major depressive disorder and post-traumatic stress disorder. The company’s research programs also explore applications in mild traumatic brain injury and Alzheimer’s-type dementias, with the goal of delivering therapies that restore neural circuitry and improve cognitive function. Headquartered in North America, Clearmind Medicine operates research facilities and partnerships across Canada and the United States. The company collaborates with academic institutions and contract research organizations to advance its drug candidates through toxicology studies and human trials. By combining proprietary medicinal chemistry with established preclinical models, Clearmind seeks to streamline development timelines and establish differentiated therapeutic profiles. Clearmind’s leadership team comprises professionals with deep expertise in neuroscience, clinical development and regulatory affairs. The company’s board and scientific advisors include experts in psychopharmacology, neurology and drug development strategy, reflecting a commitment to rigorous science and commercial execution. As a Nasdaq-listed entity, Clearmind Medicine continues to expand its research collaborations and augment its pipeline in pursuit of new treatments for underserved neurological and psychiatric indications.AI Generated. May Contain Errors. Read More Clearmind Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreCMND MarketRank™: Clearmind Medicine scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Clearmind Medicine. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearmind Medicine is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearmind Medicine is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioClearmind Medicine has a P/B Ratio of 5.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.80% of the float of Clearmind Medicine has been sold short.Short Interest Ratio / Days to CoverClearmind Medicine has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearmind Medicine has recently decreased by 43.26%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldClearmind Medicine does not currently pay a dividend.Dividend GrowthClearmind Medicine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.80% of the float of Clearmind Medicine has been sold short.Short Interest Ratio / Days to CoverClearmind Medicine has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearmind Medicine has recently decreased by 43.26%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.91 News SentimentClearmind Medicine has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.02 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Clearmind Medicine this week, compared to 1 article on an average week.Search Interest1 people have searched for CMND on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Clearmind Medicine insiders have not sold or bought any company stock.Percentage Held by Institutions96.05% of the stock of Clearmind Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Clearmind Medicine's insider trading history. Receive CMND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearmind Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CMND Stock News HeadlinesClearmind Medicine convenes inaugural Scientific Advisory Board meetingSeptember 25 at 8:50 PM | msn.comClearmind Medicine Inc. Holds Inaugural Annual Scientific Advisory Board Meeting to Advance Novel Therapeutics for Addiction and Metabolic DisordersSeptember 25 at 7:51 AM | quiverquant.comQElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.September 26 at 2:00 AM | Banyan Hill Publishing (Ad)Clearmind Medicine's Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived TherapiesSeptember 25 at 7:40 AM | globenewswire.comClearmind Medicine files to sell 17.02M common shares for holdersSeptember 19, 2025 | msn.comClearmind Medicine registers 17M shares for resale linked to $10M convertible note dealSeptember 19, 2025 | msn.comClearmind Medicine secures $10M securities purchase agreementSeptember 19, 2025 | msn.comClearmind Medicine Inc. Secures Up to $10 Million in Convertible Promissory Note FinancingSeptember 19, 2025 | quiverquant.comQSee More Headlines CMND Stock Analysis - Frequently Asked Questions How have CMND shares performed this year? Clearmind Medicine's stock was trading at $1.38 at the start of the year. Since then, CMND stock has decreased by 23.9% and is now trading at $1.05. How were Clearmind Medicine's earnings last quarter? Clearmind Medicine Inc. (NASDAQ:CMND) announced its quarterly earnings results on Thursday, September, 11th. The company reported ($0.25) EPS for the quarter. When did Clearmind Medicine's stock split? Shares of Clearmind Medicine reverse split before market open on Tuesday, November 28th 2023.The 1-30 reverse split was announced on Tuesday, November 28th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Clearmind Medicine IPO? Clearmind Medicine (CMND) raised $9 million in an initial public offering (IPO) on Tuesday, November 15th 2022. The company issued 1,300,000 shares at $6.00-$8.00 per share. Aegis Capital Corp. acted as the underwriter for the IPO. Who are Clearmind Medicine's major shareholders? Top institutional shareholders of Clearmind Medicine include AdvisorShares Investments LLC (4.82%). How do I buy shares of Clearmind Medicine? Shares of CMND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Clearmind Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearmind Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), AppLovin (APP) and e.l.f. Beauty (ELF). Company Calendar Last Earnings9/11/2025Today9/26/2025Fiscal Year End10/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CMND CIK1892500 Webwww.clearmindmedicine.com Phone604-260-1566FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.26 million Net MarginsN/A Pretax MarginN/A Return on Equity-173.87% Return on Assets-70.55% Debt Debt-to-Equity RatioN/A Current Ratio1.32 Quick Ratio1.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book5.25Miscellaneous Outstanding Shares5,470,000Free FloatN/AMarket Cap$5.74 million OptionableNot Optionable Beta0.97 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:CMND) was last updated on 9/26/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearmind Medicine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearmind Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.